The estimated Net Worth of Joseph J Wolk is at least $19 Milhão dollars as of 13 February 2024. Mr. Wolk owns over 1,780 units of Johnson & Johnson stock worth over $11,481,856 and over the last 6 years he sold JNJ stock worth over $0. In addition, he makes $7,497,690 as Chief Financial Officer e Executive Vice President at Johnson & Johnson.
Sign up
Mr. Wolk JNJ stock SEC Form 4 insiders trading
Joseph has made over 10 trades of the Johnson & Johnson stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 1,780 units of JNJ stock worth $293,380 on 13 February 2024.
The largest trade he's ever made was exercising 25,835 units of Johnson & Johnson stock on 12 February 2024 worth over $4,258,125. On average, Joseph trades about 5,511 units every 114 days since 2019. As of 13 February 2024 he still owns at least 69,663 units of Johnson & Johnson stock.
You can see the complete history of Mr. Wolk stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Joseph Wolk biography
Joseph J. Wolk is Chief Financial Officer, Executive Vice President of the Company. He was previously Vice President, Group Finance for the Pharmaceuticals Group of Johnson & Johnson, where he provided finance leadership, supporting Worldwide Chairman, Pharmaceuticals Joaquin Duato, and Chief Scientific OfficerPaul Stoffels, as a member of the Pharmaceuticals Group Operating Committee. Prior to that role, he held other finance leadership positions at Johnson & Johnson as Vice President of Finance for the Medical Devices Global Supply Chain, and as Chief Financial Officer of the North America Pharmaceuticals Group, responsible for Centocor Ortho Biotech Inc. as well as U.S. Pricing Strategy and Compliance. Wolk joined Johnson & Johnson in 1998 as a Finance Manager in the Ortho-McNeil Pharmaceutical organization. Prior to joining Johnson & Johnson, Wolk held multiple positions of increasing responsibility at Ametek, Inc. He holds a Bachelor of Science degree in Finance from St. Joseph's University, where he currently serves on the Haub School of Business Board of Visitors, and he also holds a Juris Doctor degree from Temple University School of Law and is a Certified Public Accountant.
What is the salary of Joseph Wolk?
As the Chief Financial Officer e Executive Vice President of Johnson & Johnson, the total compensation of Joseph Wolk at Johnson & Johnson is $7,497,690. There are 3 executives at Johnson & Johnson getting paid more, with Alex Gorsky having the highest compensation of $25,365,800.
How old is Joseph Wolk?
Joseph Wolk is 53, he's been the Chief Financial Officer e Executive Vice President of Johnson & Johnson since 2018. There are 28 older and 4 younger executives at Johnson & Johnson. The oldest executive at Johnson & Johnson is Ronald Williams, 70, who is the Independent Director.
What's Joseph Wolk's mailing address?
Joseph's mailing address filed with the SEC is ONE JOHNSON & JOHNSON PLAZA, , NEW BRUNSWICK, NJ, 08933.
Insiders trading at Johnson & Johnson
Over the last 22 years, insiders at Johnson & Johnson have traded over $59,929,946 worth of Johnson & Johnson stock and bought 21,998 units worth $2,578,685 . The most active insiders traders include Hubert Joly, Anne M Mulcahy, eAlex Gorsky. On average, Johnson & Johnson executives and independent directors trade stock every 21 days with the average trade being worth of $4,572,436. The most recent stock trade was executed by Robert J Decker on 30 August 2024, trading 5,635 units of JNJ stock currently worth $563,838.
What does Johnson & Johnson do?
Johnson & Johnson is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods.
What does Johnson & Johnson's logo look like?
Complete history of Mr. Wolk stock trades at Johnson & Johnson
Johnson & Johnson executives and stock owners
Johnson & Johnson executives and other stock owners filed with the SEC include:
-
Alex Gorsky,
Chairman of the Board, Chief Executive Officer -
Paulus Stoffels,
Vice Chairman- Executive Committee, Chief Scientific Officer -
Joaquin Duato,
Vice Chairman - Executive Committee -
Joseph Wolk,
Chief Financial Officer, Executive Vice President -
Jennifer Taubert,
Executive Vice President - Worldwide Chairman, Pharmaceuticals -
Michael Ullmann,
Executive Vice President, General Counsel -
Alex Gorsky,
Exec. Chairman -
Peter Fasolo,
Chief Human Resource Officer, Executive Vice President -
Dr. Paulus A. Stoffels M.D., Ph.D.,
Chief Scientific Officer -
Joaquin Duato,
CEO & Director -
Joseph J. Wolk CPA,
Exec. VP & CFO -
Joseph J. Wolk C.P.A.,
Exec. VP & CFO -
Jennifer L. Taubert,
Exec. VP & Worldwide Chairman of Pharmaceuticals -
Anne Mulcahy,
Lead Independent Director -
Charles Prince,
Independent Director -
Mary Beckerle,
Independent Director -
Ronald Williams,
Independent Director -
D. Scott Davis,
Independent Director -
A. Eugene Washington,
Independent Director -
Jennifer Doudna,
Independent Director -
Mark McClellan,
Independent Director -
Ian Davis,
Independent Director -
Marillyn Hewson,
Independent Director -
Mark Weinberger,
Independent Director -
Hubert Joly,
Independent Director -
Christopher DelOrefice,
Vice President, Investor Relations -
Kathryn Wengel,
Executive Vice President, Chief Global Supply Chain Officer -
Michael Sneed,
Executive Vice President - Global Corporate Affairs and Chief Communication Officer -
Thibaut Mongon,
Executive Vice President, Worldwide Chairman, Consumer -
Ashley McEvoy,
Executive Vice President - Worldwide Chairman, Medical Devices -
Dr. Guy J. Lebeau M.D.,
Group Chairman of MD&D Bus. - EMEA -
Dr. Peter M. Fasolo Ph.D.,
Exec. VP & Chief HR Officer -
Michael H. Ullmann,
Exec. VP & Gen. Counsel -
Jessica Moore,
VP of Investor Relations -
Ashley Watson,
Chief Compliance Officer -
James Swanson,
Exec. VP & Global CIO -
Robert J. Decker Jr.,
Controller & Chief Accounting Officer -
James Cullen,
Director -
Stephen J Cosgrove,
-
Leo F Mullin,
Director -
Michael M E Johns,
Director -
Robert J Decker,
VP Corporate Controller -
Elizabeth Forminard,
Executive VP, General Counsel -
Ronald A Kapusta,
Controller, CAO -
Susan L Lindquist,
Director -
Gary J Pruden,
Exec VP, WW Chair, Med Devices -
William D Perez,
Director -
Jorge S. Mesquita,
Exec VP, WW Chair, Consumer -
Dominic J Caruso,
Chief Financial Officer -
Timothy Schmid,
EVP, WW Chair, MedTech -
Mary Sue Coleman,
Director -
David Satcher,
Director -
William C Weldon,
Chairman/CEO -
Arnold G Langbo,
Director -
Russell C Deyo,
Vice President, Administration -
Kaye I Foster Cheek,
VP, Human Resources -
Colleen A Goggins,
Member, Executive Committee -
Sherilyn S Mc Coy,
Member, Executive Committee -
Donald M Jr. Casey,
Member, Executive Committee -
Nicholas J Valeriani,
Vice President,Human Resources -
Christine A Poon,
Executive Committee Member -
Joseph C Scodari,
Executive Committee Member -
Steven Reinemund,
Director -
Ann Dibble Jordan,
Director -
Robert J Darretta,
Member, Executive Committee -
Per A Peterson,
Executive Committee Member -
Michael J Dormer,
Member, Executive Committee -
Joann Heffernan Heisen,
Member, Executive Committee -
Gerard N Burrow,
Director -
Henry B Schacht,
Director -
M Judah Folkman,
Director -
Roger S Fine,
Vice President General Counsel -
James T Lenehan,
Vice Chairman -
Brian D Perkins,
Executive Committee Member -
Robert N Wilson,
-
Nadja West,
Director -
Vanessa Broadhurst,
EVP, Global Corp Affairs -
Mathai Mammen,
EVP, Pharm, R&D -
William Hait,
EVP, Chief EI and Med Officer -
Darius Adamczyk,
Director -
James D. Swanson,
EVP, CIO -
John C Reed,
EVP, Innovative Medicine, R&D -
Paula A Johnson,
Director -
Eugene A. Woods,
Director